Cargando…
Extracellular Vesicles in Myeloid Neoplasms
Myeloid neoplasms arise from malignant primitive cells, which exhibit growth advantage within the bone marrow microenvironment (BMM). The interaction between these malignant cells and BMM cells is critical for the progression of these diseases. Extracellular vesicles (EVs) are lipid bound vesicles s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369333/ https://www.ncbi.nlm.nih.gov/pubmed/35955960 http://dx.doi.org/10.3390/ijms23158827 |
_version_ | 1784766419766870016 |
---|---|
author | Karantanou, Christina Minciacchi, Valentina René Karantanos, Theodoros |
author_facet | Karantanou, Christina Minciacchi, Valentina René Karantanos, Theodoros |
author_sort | Karantanou, Christina |
collection | PubMed |
description | Myeloid neoplasms arise from malignant primitive cells, which exhibit growth advantage within the bone marrow microenvironment (BMM). The interaction between these malignant cells and BMM cells is critical for the progression of these diseases. Extracellular vesicles (EVs) are lipid bound vesicles secreted into the extracellular space and involved in intercellular communication. Recent studies have described RNA and protein alterations in EVs isolated from myeloid neoplasm patients compared to healthy controls. The altered expression of various micro-RNAs is the best-described feature of EVs of these patients. Some of these micro-RNAs induce growth-related pathways such as AKT/mTOR and promote the acquisition of stem cell-like features by malignant cells. Another well-described characteristic of EVs in myeloid neoplasms is their ability to suppress healthy hematopoiesis either via direct effect on healthy CD34+ cells or via alteration of the differentiation of BMM cells. These results support a role of EVs in the pathogenesis of myeloid neoplasms. mainly through mediating the interaction between malignant and BMM cells, and warrant further study to better understand their biology. In this review, we describe the reported alterations of EV composition in myeloid neoplasms and the recent discoveries supporting their involvement in the development and progression of these diseases. |
format | Online Article Text |
id | pubmed-9369333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93693332022-08-12 Extracellular Vesicles in Myeloid Neoplasms Karantanou, Christina Minciacchi, Valentina René Karantanos, Theodoros Int J Mol Sci Review Myeloid neoplasms arise from malignant primitive cells, which exhibit growth advantage within the bone marrow microenvironment (BMM). The interaction between these malignant cells and BMM cells is critical for the progression of these diseases. Extracellular vesicles (EVs) are lipid bound vesicles secreted into the extracellular space and involved in intercellular communication. Recent studies have described RNA and protein alterations in EVs isolated from myeloid neoplasm patients compared to healthy controls. The altered expression of various micro-RNAs is the best-described feature of EVs of these patients. Some of these micro-RNAs induce growth-related pathways such as AKT/mTOR and promote the acquisition of stem cell-like features by malignant cells. Another well-described characteristic of EVs in myeloid neoplasms is their ability to suppress healthy hematopoiesis either via direct effect on healthy CD34+ cells or via alteration of the differentiation of BMM cells. These results support a role of EVs in the pathogenesis of myeloid neoplasms. mainly through mediating the interaction between malignant and BMM cells, and warrant further study to better understand their biology. In this review, we describe the reported alterations of EV composition in myeloid neoplasms and the recent discoveries supporting their involvement in the development and progression of these diseases. MDPI 2022-08-08 /pmc/articles/PMC9369333/ /pubmed/35955960 http://dx.doi.org/10.3390/ijms23158827 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Karantanou, Christina Minciacchi, Valentina René Karantanos, Theodoros Extracellular Vesicles in Myeloid Neoplasms |
title | Extracellular Vesicles in Myeloid Neoplasms |
title_full | Extracellular Vesicles in Myeloid Neoplasms |
title_fullStr | Extracellular Vesicles in Myeloid Neoplasms |
title_full_unstemmed | Extracellular Vesicles in Myeloid Neoplasms |
title_short | Extracellular Vesicles in Myeloid Neoplasms |
title_sort | extracellular vesicles in myeloid neoplasms |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369333/ https://www.ncbi.nlm.nih.gov/pubmed/35955960 http://dx.doi.org/10.3390/ijms23158827 |
work_keys_str_mv | AT karantanouchristina extracellularvesiclesinmyeloidneoplasms AT minciacchivalentinarene extracellularvesiclesinmyeloidneoplasms AT karantanostheodoros extracellularvesiclesinmyeloidneoplasms |